Stay updated with breaking news from Lexaria Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antiviralsKELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company"
Press release content from Accesswire. The AP news staff was not involved in its creation.
HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefitsThis study is designed to enhance Lexaria's probabilities of success with its expected
Recent developments of interest in cardiovascular medicine
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug